JP2025508943A5 - - Google Patents

Info

Publication number
JP2025508943A5
JP2025508943A5 JP2024551973A JP2024551973A JP2025508943A5 JP 2025508943 A5 JP2025508943 A5 JP 2025508943A5 JP 2024551973 A JP2024551973 A JP 2024551973A JP 2024551973 A JP2024551973 A JP 2024551973A JP 2025508943 A5 JP2025508943 A5 JP 2025508943A5
Authority
JP
Japan
Prior art keywords
alternatively
alkyl
group
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508943A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/014293 external-priority patent/WO2023167938A1/en
Publication of JP2025508943A publication Critical patent/JP2025508943A/ja
Publication of JP2025508943A5 publication Critical patent/JP2025508943A5/ja
Pending legal-status Critical Current

Links

JP2024551973A 2022-03-02 2023-03-01 ウイルス感染症の治療のための化合物及び方法 Pending JP2025508943A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315919P 2022-03-02 2022-03-02
US63/315,919 2022-03-02
US202263413748P 2022-10-06 2022-10-06
US63/413,748 2022-10-06
PCT/US2023/014293 WO2023167938A1 (en) 2022-03-02 2023-03-01 Compounds and methods for treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2025508943A JP2025508943A (ja) 2025-04-10
JP2025508943A5 true JP2025508943A5 (cg-RX-API-DMAC10.html) 2026-03-10

Family

ID=85772852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551973A Pending JP2025508943A (ja) 2022-03-02 2023-03-01 ウイルス感染症の治療のための化合物及び方法

Country Status (8)

Country Link
US (1) US20230322813A1 (cg-RX-API-DMAC10.html)
EP (1) EP4486746A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025508943A (cg-RX-API-DMAC10.html)
KR (1) KR20240154646A (cg-RX-API-DMAC10.html)
AU (1) AU2023227470A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243944A1 (cg-RX-API-DMAC10.html)
TW (2) TWI878811B (cg-RX-API-DMAC10.html)
WO (1) WO2023167938A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN119039322A (zh) * 2023-09-19 2024-11-29 广东晨康生物科技有限公司 一种环碳酸酯核苷化合物的盐、晶体及其制备方法和应用
CN119792537B (zh) * 2025-01-22 2025-10-21 常州大学 利巴韦林与pd-1抑制剂联合用药物组合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
EP1646371A4 (en) 2003-06-26 2010-09-22 Biotron Ltd ANTIVIRAL COMPOSITIONS AND METHODS
US8669280B2 (en) 2005-06-24 2014-03-11 Biotron Limited Antiviral compounds and methods
ES2614269T3 (es) 2007-08-03 2017-05-30 Biotron Limited Procedimientos y composiciones antivíricas frente a la hepatitis C
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
PE20160686A1 (es) 2014-01-30 2016-07-23 Hoffmann La Roche Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3250685A1 (en) 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Recombinant hbv cccdna, the method to generate thereof and the use thereof
JP6435054B2 (ja) 2015-02-11 2018-12-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染の治療及び予防のための新規2−オキソ−6,7−ジヒドロベンゾ[a]キノリジン−3−カルボン酸誘導体
WO2017184668A1 (en) * 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
BR112019016316A2 (pt) 2017-02-08 2020-03-31 Biotron Limited Métodos para o tratamento da influenza
KR20220132608A (ko) * 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
IL299202A (en) * 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
US11926645B2 (en) * 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
CN114181258B (zh) * 2021-12-29 2023-10-13 南京师范大学 用于抗病毒治疗的核苷类化合物及用途
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用

Similar Documents

Publication Publication Date Title
JP2025508942A5 (cg-RX-API-DMAC10.html)
CN112778310B (zh) 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
JP2005533824A5 (cg-RX-API-DMAC10.html)
JP2023540225A5 (cg-RX-API-DMAC10.html)
JP2010539241A5 (cg-RX-API-DMAC10.html)
JP2011521903A5 (cg-RX-API-DMAC10.html)
RU2468029C2 (ru) Ингибиторы hcv ns3 протеазы
JP2023551174A5 (cg-RX-API-DMAC10.html)
RU2019118390A (ru) Производное пиразоло-гетероарила, способ его получения и медицинское применение
JP2011518835A5 (cg-RX-API-DMAC10.html)
RU2011133741A (ru) Модифицированные 2'- и 3'-нуклеозиды и их применение для получения лекарственного средства для лечения инфекций flaviviridae
JP2015523365A5 (cg-RX-API-DMAC10.html)
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
JP2022505597A5 (cg-RX-API-DMAC10.html)
JP2013056886A5 (cg-RX-API-DMAC10.html)
JP2012517444A5 (cg-RX-API-DMAC10.html)
JP2006528700A5 (cg-RX-API-DMAC10.html)
CA2490200A1 (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
JPH11512083A (ja) C型肝炎の治療における1,3−オキサチオランヌクレオシドアナログ
JP2015525220A5 (cg-RX-API-DMAC10.html)
EA201490903A1 (ru) Композиции и способы лечения вирусного гепатита c
RU2014113539A (ru) Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
JP2021521118A (ja) 肝硬変を伴うhcv感染患者の治療
JP2025096283A5 (cg-RX-API-DMAC10.html)
JP2018512453A5 (cg-RX-API-DMAC10.html)